Related Experiment Videos
Insights
The Beta Blocker Heart Attack Trial (BHAT) demonstrated that propranolol significantly reduces mortality in patients after a heart attack. This study provides key evidence for beta-blocker use in post-myocardial infarction care.
Area of Science:
- Cardiology
- Clinical Trials
- Pharmacology
Background:
- Acute myocardial infarction survivors face elevated mortality risks.
- Beta-blockers are hypothesized to improve outcomes post-heart attack.
Purpose of the Study:
- To evaluate the efficacy of propranolol in reducing total mortality in patients post-myocardial infarction.
- To assess other fatal and nonfatal response variables in this patient cohort.
Main Methods:
- A multicenter, randomized, double-blind, placebo-controlled trial involving 3,837 patients aged 30-69.
- Patients were followed for 2-4 years post-infarction at 31 clinical centers.
- Key design features included patient logs, informed consent, serum drug level monitoring, and ambulatory electrocardiogram comparisons.
Main Results:
- Propranolol administration was effective in reducing total mortality.
- Specific data on fatal and nonfatal outcomes were systematically monitored.
Conclusions:
- Regular propranolol administration is beneficial for reducing mortality in patients who have survived a recent acute myocardial infarction.
- The study validates the use of beta-blockers as a critical component of post-heart attack management.
Abstract:
The Beta Blocker Heart Attack Trial (BHAT) is a multicenter, randomized, double-blind, placebo control clinical trial sponsored by the National Heart, Lung, and Blood Institute designed to test the effectiveness of regular propranolol administration in reducing total mortality in patients who have survived a recent acute myocardial infarction. A number of other fatal and nonfatal response variables are also being monitored. Three thousand eight hundred thirty-seven patients, ages 30-69, are being followed at 31 clinical centers for a minimum of about 2 and a maximum of 4 years after the infarction. A number of design features of BHAT are discussed. These include maintenance of patient logs, guidelines for obtaining informed consent of patients, assessment of patient knowledge about BHAT, adjustment of study drug dose based on serum levels, and comparison of 1-hr and 24-hr ambulatory electrocardiogram readings.